Goldman Sachs Reiterates Neutral on Acceleron Pharma, Raises Price Target to $81

Goldman Sachs analyst Paul Choi reiterates Acceleron Pharma (NASDAQ:XLRN) with a Neutral and raises the price target from $47 to $81.

Benzinga · 01/28/2020 13:21

Goldman Sachs analyst Paul Choi reiterates Acceleron Pharma (NASDAQ:XLRN) with a Neutral and raises the price target from $47 to $81.